Symbolbild · KI-generiert
Pharmala Biotech Holdings Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Pharmala is focused on manufacture of Active Pharmaceutical Ingredients, of the Substituted methylenedioxy- phenethylamines class (“MDXX”), including 3,4-Methylenedioxymethamphetamine (“MDMA”). Pharmala also intends to undertake development of novel formulations of MDMA and the MDXX class of compounds, as well as developing novel drug delivery pathways for these molecules.
Company description as published by the issuer via Canadian Securities Exchange.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Pharmala Biotech Holdings Inc. | MDMA | CSE | 12 Mio. USD |
| KDA Group Inc. | KDA | TSXV | 12 Mio. USD |
| Izotropic Corporation | IZO | CSE | 12 Mio. USD |
| Nanalysis Scientific Corp. | NSCI | TSXV | 12 Mio. USD |
| VVT Med Inc. | VVTM | TSXV | 11 Mio. USD |
| MedX Health Corp. | MDX | TSXV | 13 Mio. USD |
| Principal Technologies Inc. | PTEC | TSXV | 13 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.